Daiwa Securities Group Inc. Has $61,000 Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Daiwa Securities Group Inc. reduced its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 13.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,360 shares of the company’s stock after selling 4,178 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Allogene Therapeutics were worth $61,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Arizona State Retirement System boosted its stake in Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after purchasing an additional 10,855 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Allogene Therapeutics by 82.7% in the second quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock valued at $1,862,000 after purchasing an additional 361,904 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Allogene Therapeutics by 8.2% during the second quarter. Rhumbline Advisers now owns 164,508 shares of the company’s stock valued at $383,000 after buying an additional 12,473 shares during the last quarter. Rothschild Investment LLC bought a new stake in Allogene Therapeutics during the second quarter worth $52,000. Finally, Bank of New York Mellon Corp raised its position in Allogene Therapeutics by 20.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 362,364 shares of the company’s stock valued at $844,000 after buying an additional 61,811 shares during the last quarter. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Price Performance

Shares of ALLO opened at $2.88 on Wednesday. The firm has a market cap of $601.92 million, a PE ratio of -1.61 and a beta of 0.83. Allogene Therapeutics, Inc. has a 1 year low of $2.01 and a 1 year high of $5.78. The stock’s fifty day moving average price is $2.69 and its two-hundred day moving average price is $3.08.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. Sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALLO has been the subject of several recent analyst reports. Piper Sandler assumed coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They issued an “overweight” rating and a $11.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, August 15th. Truist Financial reiterated a “buy” rating and issued a $14.00 price objective (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Citigroup upped their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Oppenheimer initiated coverage on Allogene Therapeutics in a report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.96.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).